News
Latest News, Announcements, and Press Releases
14Feb 19
Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria
REDWOOD CITY, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of…
read more06Feb 19
Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan
REDWOOD CITY, Calif. , Feb. 06, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron,…
read more04Feb 19
Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck
REDWOOD CITY, Calif. , Feb. 04, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a subsidiary. Under the terms of the agreement, Codexis will install…
read more08Nov 18
Codexis Reports Third Quarter 2018 Financial Results
Total revenues increase 70% to $16.9 million driven by higher product revenue and R&D revenue across an increased number of customers Conference call begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) —…
read more08Nov 18
Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114
CDX-6114 meets safety and tolerability endpoints REDWOOD CITY, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces top-line results from its Phase 1a single ascending-dose study in healthy volunteers with CDX-6114,…
read more07Nov 18
Codexis to Present at Two Investment Conferences in November
REDWOOD CITY, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will present at two upcoming investment conferences: 9 th Annual Craig-Hallum Alpha Select Conference on Thursday, November 15,…
read more01Nov 18
Codexis to Hold Third Quarter 2018 Conference Call on November 8
REDWOOD CITY, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report third quarter 2018 financial results after market close on Thursday, November 8, 2018 . Codexis management…
read more01Oct 18
Codexis Appoints Claus Ladefoged to Global Enzyme Business Development Role
REDWOOD CITY, Calif. , Oct. 01, 2018 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the appointment of Claus Ladefoged as Director, Enzyme Business Development . Ladefoged has extensive experience in successfully building relationships and
read more11Sep 18
National Association For Business Resources Announces San Francisco Bay Area’s Best And Brightest Companies To Work For® Winners
Codexis is pleased to announce we’ve been selected as one of the nation’s Best and Brightest Companies to Work For®. September 11, 2018 – San Francisco, CA — Companies that excel at employee relations, use innovation to motivate employees, implement…
read more29Aug 18
Codexis to Present at Three Investment Conferences in September
REDWOOD CITY, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at three upcoming investment conferences: H.C. Wainwright 20 th Annual Global investment Conference on Wednesday, September 5,…
read moreSince 2002, Codexis has created new technologies to unlock the power of proteins®. Put our unmatched protein engineering expertise to work for you.
Unlock the power of proteins® with Codexis
Learn More
Company
Industries